$0.49
1.21% today
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US00444T1007
Symbol
TLPH

AcelRx Pharmaceuticals, Inc. Stock price

$0.49
+0.09 23.18% 1M
-0.05 9.13% 6M
-0.03 5.99% YTD
-0.41 45.26% 1Y
-6.55 93.00% 3Y
-24.91 98.06% 5Y
-76.11 99.36% 10Y
-90.51 99.46% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.01 1.21%
ISIN
US00444T1007
Symbol
TLPH
Industry

Key metrics

Basic
Market capitalization
$10.0m
Enterprise Value
$4.6m
Net debt
positive
Cash
$5.4m
Shares outstanding
17.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
333.0 | 362.7
EV/Sales
153.4 | 167.0
EV/FCF
negative
P/B
1.8
Financial Health
Equity Ratio
43.9%
Return on Equity
-162.5%
ROCE
-107.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$30.0k | $27.5k
EBITDA
- | -
EBIT
$-13.9m | $-16.0m
Net Income
$-11.6m | $-7.0m
Free Cash Flow
$-13.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -4.9%
Net Income
- | 46.3%
Free Cash Flow
12.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-51,596.3%
Net
-43,122.2% | -25,333.3%
Free Cash Flow
-49,148.2%
More
EPS
$-0.5
FCF per Share
$-0.8
Short interest
0.2%
Employees
13
Rev per Employee
$0.0
Show more

Is AcelRx Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

AcelRx Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

Buy
89%
Hold
11%

Financial data from AcelRx Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.03 0.03
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.50 7.50
-
25,000%
- Research and Development Expense 6.45 6.45
-
21,500%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -14 -14
-
-46,437%
Net Profit -12 -12
-
-38,800%

In millions USD.

Don't miss a Thing! We will send you all news about AcelRx Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AcelRx Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
8 days ago
Talphera, Inc. (NASDAQ:TLPH ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Raffi Mark Asadorian - Chief Financial Officer Shakil Aslam - Chief Medical Officer Vincent J. Angotti - CEO & Director Conference Call Participants Antonio Eduardo Arce - WestPark Capital, Inc. James Francis Molloy - Alliance Global Partners, Research Division Nazibur Rahman - Maxim G...
Neutral
PRNewsWire
8 days ago
New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday, August 14, 2025 at 4:30 pm ET SAN MATEO, Calif. , Aug. 14, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH)...
Neutral
PRNewsWire
15 days ago
SAN MATEO, Calif. , Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and ...
More AcelRx Pharmaceuticals, Inc. News

Company Profile

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Head office United States
CEO Vincent Angotti
Employees 13
Founded 2005
Website talphera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today